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Background/aim: β1-selective beta-blockers (BBs) are sympatholytic agents, and discerning their effects on bone health would be of
great importance. This study aimed to investigate the influence of β1-selective BBs on bone mineral density (BMD) and fracture risk.
Materials and methods: This study included postmenopausal women who used β1-selective BBs (BB group) and control group.
Sociodemographic characteristics, BMD and previous fragility fractures were recorded. Additionally, the 10-year probability of a major
osteoporotic and hip fracture was calculated using the fracture risk assessment tool (FRAX).
Results: A total of 60 participants were included in the study. L1-4 and L2-4 BMD values were significantly higher in BB group than
control group (P = 0.015 and P = 0.025, respectively). Moreover, T-scores of lumbar and femur total were significantly higher in the
BB group. Two patients in BB and 6 patients in control group had previous fragility fracture. No statistically significant intergroup
difference was noted regarding FRAX.
Conclusion: Based on our results, β1-selective BB usage was associated with higher BMD at the lumbar region in postmenopausal
women.
Keywords: Adrenergic beta-antagonists, postmenopause, bone mineral density

1. Introduction.
Osteoporosis is a disease with worldwide prevalence.
It decreases bone mass and strength, thereby resulting
in fractures and primarily affects postmenopausal
women [1–3]. Almost, 40% postmenopausal women
have osteoporosis [4]. A deterioration in bone mass
and strength with aging is an expected situation
besides the several factors that may affect bone mass
and strength, such as inflammation, endocrinological
and metabolic disorders and some drugs [5–7].
Recent studies have shown that the sympathetic
nervous system significantly affects bone metabolism
[8–12]. Typically, sympathetic activation is considered
to contribute to bone loss [13]. This effect was believed
to be mainly mediated by β2 adrenergic receptors [9–
11]. However, some researchers have shown that β1 and
β3 adrenergic receptors are also present in the human
periosteal osteoblasts and human osteosarcomaderived cells [14].
Beta-blockers (BBs), especially β1-selective BBs, are
the commonly used sympatholytic agents and find use

in several cardiovascular diseases such as hypertension,
arrhythmias, myocardial infarction, congestive heart
failure and angina pectoris [15]. Osteoporosis and
cardiovascular diseases often occur together during
the postmenopausal period [16]. Several studies
have investigated the effects of nonselective BBs on
fracture risk and bone mineral density (BMD), albeit
with conflicting results [16–20]. In contrast, some
researchers have found β1 receptors in the human
periosteal osteoblasts, which makes it imperative
to determine the effects of β1-selective BBs on bone
health. In a previous study, it was concluded that
metoprolol prevented the bone loss in ovariectomized
rats [21].
This study aimed to investigate the effects of β1selective BBs on BMD, fragility fracture and the 10year predicted probability of major osteoporotic and
hip fractures. To our knowledge, no investigation
has yet been done regarding the 10-year predicted
probability of major osteoporotic and hip fractures in
postmenopausal women using β1-selective BBs.
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2. Materials and methods
2.1. Study design and subjects
This cross-sectional study has been approved by the local
ethics committee of Bakırköy Dr. Sadi Konuk Training
Hospital (2018/57) and has been performed per the ethical
standards laid down in the 1964 Declaration of Helsinki
and its later amendments. Informed consent was obtained
from the subjects.
Postmenopausal women who were admitted to
the outpatient clinic İstanbul Physical Medicine and
Rehabilitation Training and Research Hospital between
January 2018 and September 2018 were evaluated for this
study. Women who had not menstruated for at least 1year
were considered menopausal as per the definition of the
World Health Organization [22].
Criteria for exclusion were as follows: Older than 65
years, abnormality in laboratory tests (complete blood
count, serum creatinine, calcium, phosphorus), endocrine
disorders, chronic liver disease, history of steroid use
(at any time more than 3 months), anticonvulsant and
anticoagulant drug use, acute and chronic infectious
disease, inflammatory disease, history of malignancy,
secondary osteoporosis and undergoing treatment for
osteoporosis. Because of the potential impact on bone
turnover, patients who used a drug for more than 3 months
besides β1-selective BBs were excluded from the study. The
study comprised 2 groups: BB and control groups. The
control group included postmenopausal women who were
age- and menopause duration-matched with those of the
BB group and had no history of BBs usage. The minimum
BB usage period was determined as 6 months in the BB
group and all women in BB were using β1-selective BBs
when included in the study.
2.2. Methods
2.2.1.Demographic characteristics
Age (year), height (cm), weight (kg), body mass index
(BMI, kg/m2) and time after the last menstruation cycle
(year) of the participants were recorded. Additionally,
the participants were also asked about their smoking
status, alcohol intake, regular exercise, previous fragility
fracture with the timing of the fracture (premenopausal
or postmenopausal) and history of hip fracture in the
family. Fractures that occurred during childhood were
not recorded. An exercise regime of more than 30 min at
least thrice a week was considered as regular exercise. The
period of β1-selective BBs use was recorded for patients of
BBs group per the information received from them.
2.2.2. Bone mineral density
The BMD was measured at the lumbar spine and femur by
using dual-energy X-ray absorptiometry (DPX-LUNAR
74400). Lumbar spine (L1-4;L2-4), femur neck and femur
total T-scores and BMD (g/cm2) were recorded.

2.2.3. Fracture risk assessment tool (FRAX)
FRAX calculates the 10-year fracture probability of a major
osteoporotic (FRAX-major) and hip fracture (FRAXhip) by using some variables (age, BMI, previous fracture,
parent hip fracture, current smoking, glucocorticoid use,
alcohol consumption, rheumatoid arthritis and secondary
osteoporosis). FRAX-hip and FRAX-major of subjects were
calculated using the Turkish version of the FRAX assessment
tool [23,24].
2.3. Sample size
Power analysis was performed with reference to a previous
study to determine the minimum number of participants
planned to be included in the study [25]. Minimum 26
participants for each group were needed to achieve the
effect size (d = 0.84) of the previous study with alfa error
probability of 0.05 and 80% power.
2.4. Statistical analysis
Statistical studies were performed using the MedCalc
software, version 18.11.3. Descriptive statistics were
shown as the mean ± standard deviation for continuous
variables, and nominal variables were presented as the
number of cases and percentages (%). Normality was tested
by Kolmogorow-Smirnov test for continuous variables.
Intergroup comparisons of the various parameters were
performed using the independent-samples t-test and the
chi-square test wherever applicable. Pearson method was
used to calculate the correlation rho. A value of P < 0.05 was
considered statistically significant.
3. Results
This study evaluated 215 postmenopausal women, of which
60 women who met the study criteria were included. The BB
and control group each comprised 30 subjects with a mean
age of 57.86 ± 5.66 in the BB group and 55.41 ± 5.9 in the
control group. Mean cessation of menstruation was 9.14 ±
5.73 years in BB group and 9.45 ± 6.96 years in the control
group. The average period of β1-selective BBs use was 42.6 ±
36.7 months. No statistically significant difference was found
in the mean age, cessation of menstruation, weight, height,
BMI, smoking and regular exercise. Alcohol consumption
was absent in both groups. There were 2 subjects in the BB
group and 6 in the control group who had a previous fracture
(P = 0.132). The previous fractures noted in the BB group
were that of the foot and costa. The control group had prior
fractures in the hip, proximal tibia, proximal humerus, foot
and two in the forearm. All these fractures occurred during
the postmenopausal period. The fractures in the BB group
occurred during BB usage. The demographic and general
features of each group are shown in Table 1.
Lumbar spine (L1-4 and L2-4) BMD values were
significantly higher in BB group compared with the control
group (P = 0.015 and P = 0.025, respectively). Additionally,
T-scores of lumbar spine (L1-4 and L2-4) and femur total
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were significantly higher in BB group (P = 0.02, P = 0.016
and P = 0.006, respectively) compared with the control
group. No statistically significant intergroup difference
was found regarding the 10-year fracture probability of
a major osteoporotic and hip fracture. Table 2 shows the
comparison of BMDs, T-scores, FRAX-major and FRAXhip of the 2 groups.
4. Discussion
In this study, we investigated the effects of β1-selective
BB use on bone health in postmenopausal women. Based
on the study results, β1-selective BB use was associated
with higher BMD in the lumbar region. Additionally, the
lumbar and femoral total T-scores were better in the BB
group compared with the control group.

Farr et al. showed that sympathetic activity was
2–4 -fold higher in postmenopausal women than in
premenopausal women [26]. Furthermore, evidence
suggests that sympathetic activity has a deleterious effect
on bones [27]. Takeda et al. showed that leptin regulates
bone formation through the sympathetic nervous system
and the systemic administration of nonselective BBs
increases bone mass [8]. Furthermore, they reported
that leptin affects the osteoblasts through β2 adrenergic
receptors. Subsequent studies have shown the presence of
β1 and β3 adrenergic receptors in the bone [14].
Zhang et al. investigated the effects of metoprolol (β1selective BB) on osteoblasts in ovariectomised rats. They
concluded that metoprolol prevents oestrogen deficiencyinduced bone loss and recommended metoprolol as an

Table 1.The demographic features of the groups.
BBs group
(N = 30)

Control group
(N = 30)

p

Age (years)

57.9 ± 5.7

55.4 ± 5.9

0.113a

Weight (kg)

75.6 ± 9.9

69.9 ± 2.2

0.097 a

Height (cm)

154.8 ± 5.5

156.2 ± 4.5

0.366 a

BMI (kg/m2)

31.4 ± 4.3

28.7 ± 4.4

0.056 a

Cessation of menstruation (years)

9.1 ± 5.7

9.4 ± 6.9

0.857 a

Smoking (%)

10

20

0.138 b

Alcohol (%)

0

0

Previous fracture (n)

2

6

0.132 b

Regular exercise (%)

16.6

3.3

0.087 b

BMI: Body mass index, (mean ± SD), a Independent-samples t-test, b Chi-square test. *P < 0.05.
Table 1.The demographic features of the groups.
BBs group
(N = 30)

Control group
(N = 30)

P

L1-4 BMD (g/cm2)

0.9±0.2

0.8 ± 0.1

0.015*

L2-4 BMD (g/cm )

0.9 ± 0.2

0.8 ± 0.1

0.025*

Femur neck BMD (g/cm2)

0.8 ± 0.0

0.8 ± 0.1

0.296

Femur total BMD (g/cm2)

0.9 ± 0.0

0.9 ± 0.1

0.065

L1-4 T-score

-1.4 ± 1.3

-2.1 ± 0.7

0.020*

L2-4 T-score

-1.3 ± 1.4

-2.1 ± 0.7

0.016*

Femur neck T-score

-0.5 ± 0.9

-0.9 ± 0.7

0.141

Femur total T-Score

-0.4 ± 0.6

-1 ± 0.8

0.006*

Frax-major fracture (%)

4.7 ± 2.0

5.3 ± 2.7

0.412

Frax-hip fracture (%)

0.5 ± 0.4

0.9 ± 0.8

0.078

2

*P < 0.05. Values are expressed as mean ± standard deviation,
BMD: Bone mineral density, FRAX: Fracture risk assesment tool.
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alternative treatment for postmenopausal osteoporosis
in hypertensive patients [21]. Furthermore, Khosla et al.
showed that the trabecular bone volume and trabecular
number were significantly better in the patients using β1selective BB group, but there was no significant difference
in cortical bone parameters [28]. Concordant with this
result, our BB group showed better BMD values in the
lumbar region where the trabecular bone is predominant.
In contrast, no significant difference was detected in the
BMD and T-score of the femoral neck where the cortical
bone is predominant. Another study has also shown a
negative correlation between sympathetic activity and
trabecular bone [21].
In this study, we also evaluated the 10-year probability
of a major osteoporotic and hip fracture in participants
by using FRAX. Based on our results, the mean value of
the 10-year predicted probability of major fracture was
4.69% in the BB group and 5.35% in the control group.
Even though the mean value of major hip fracture risk was
0.48% in the BB group and 0.87% in the control group,
the intergroup difference was not statistically significant.
Tuzun et al. found the mean 10-year major osteoporotic
fracture probability to be 6.0% and that of hip fracture to
be 2% in Turkish population aged 50 years or more [29].
The major osteoporotic and hip fracture probabilities in
postmenopausal women were determined as 5.5% and
0.9%, respectively, per a previous study result, which is
similar to the FRAX results of our control group [30].
Furthermore, there were 2 subjects with a previous
fragility fracture in the BB group and 6 subjects in the
control group. Considering this result, the fracture rate in
the control group seems slightly higher, but the intergroup
difference was not statistically significant. The findings
of a meta-analysis that investigated the effects of BBs on
fracture suggested that the risk of fracture is about 15%
lower in patients treated with BB and this effect has been
mostly attributed to β1-selective BB by authors [15].
To our knowledge, the 10-year predicted probability of
major osteoporotic and hip fracture was not investigated

before in postmenopausal women using β1-selective BBs,
which is a significant strength of our study. Moreover,
we excluded the subjects who took other drugs besides
BBs to eliminate their effects on bone, which is another
advantage of the present study. Even though β1-selective
BBs are commonly used drugs, it was some hard to find
the subjects who only used β1-selective BBs without other
cardiovascular and other medications because we wanted
to evaluate only the effects of β1-selective BB on the bone.
Notably, most of the women using β1-selective BBs were
also taking other drugs.
Nonetheless, this study has some limitations. First, this
was a cross-sectional study. Therefore, further prospective,
randomised, controlled studies in the future may provide
health professionals with more information regarding
fracture risk and BMD in subjects using β1-selective BBs.
Second, subjects who regularly exercised were more likely
to be in the BB group, although there was no statistically
significant difference. However, this may have positively
contributed to BMD.
In conclusion, β1-selective BB usage was associated
with higher BMD at the lumbar region in postmenopausal
women. The dual beneficial effects of β1-selective BBs
on both the cardiovascular and skeletal systems in
postmenopausal women can be advantageous for patients
who are required to use these drugs for a long time or
sometimes for a lifetime.
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